Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $141,236 - $278,329
37,663 Added 260.28%
52,133 $330,000
Q2 2022

Aug 15, 2022

BUY
$2.94 - $5.23 $3,528 - $6,276
1,200 Added 9.04%
14,470 $60,000
Q1 2022

May 16, 2022

BUY
$4.07 - $10.6 $54,008 - $140,662
13,270 New
13,270 $64,000
Q4 2021

Feb 14, 2022

SELL
$8.96 - $16.31 $58,007 - $105,590
-6,474 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$11.24 - $21.0 $41,194 - $76,965
3,665 Added 130.47%
6,474 $124,000
Q2 2021

Aug 16, 2021

SELL
$18.04 - $22.09 $120,380 - $147,406
-6,673 Reduced 70.38%
2,809 $90,000
Q1 2021

May 17, 2021

BUY
$16.59 - $33.89 $12,459 - $25,451
751 Added 8.6%
9,482 $286,000
Q4 2020

Feb 16, 2021

BUY
$27.5 - $37.92 $13,062 - $18,012
475 Added 5.75%
8,731 $378,000
Q3 2020

Nov 16, 2020

SELL
$34.44 - $43.75 $302,142 - $383,818
-8,773 Reduced 51.52%
8,256 $445,000
Q2 2020

Aug 14, 2020

BUY
$27.12 - $45.97 $456,592 - $773,950
16,836 Added 8723.32%
17,029 $1.04 Million
Q1 2020

May 15, 2020

BUY
$26.16 - $63.5 $5,048 - $12,255
193 New
193 $9,000
Q2 2019

Aug 14, 2019

SELL
$75.84 - $105.21 $18,808 - $26,092
-248 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$64.44 - $104.11 $15,014 - $24,257
233 Added 1553.33%
248 $39,000
Q4 2018

Feb 14, 2019

BUY
$59.1 - $93.26 $886 - $1,398
15 New
15 $1,000
Q3 2018

Nov 14, 2018

SELL
$88.86 - $117.49 $47,717 - $63,092
-537 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$99.64 - $127.59 $31,785 - $40,701
319 Added 146.33%
537 $84,000
Q1 2018

May 15, 2018

BUY
$105.8 - $150.94 $22,218 - $31,697
210 Added 2625.0%
218 $37,000
Q4 2017

Feb 14, 2018

BUY
$81.25 - $130.7 $650 - $1,045
8
8 $1,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $644M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.